LUMO Stock Overview
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lumos Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.45 |
| 52 Week High | US$4.55 |
| 52 Week Low | US$2.41 |
| Beta | 0.35 |
| 1 Month Change | -7.20% |
| 3 Month Change | -16.67% |
| 1 Year Change | -20.20% |
| 3 Year Change | -79.58% |
| 5 Year Change | n/a |
| Change since IPO | -72.03% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
Aug 25
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?
Mar 13Lumos Pharma announces new buyback program
Aug 16Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Mar 22Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth
Nov 04What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?
Dec 09Lumos Pharma (LUMO) Investor Presentation - Slideshow
Nov 17Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 11Shareholder Returns
| LUMO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.9% | -4.2% | -3.7% |
| 1Y | -20.2% | -2.0% | 20.5% |
Return vs Industry: LUMO underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: LUMO underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| LUMO volatility | |
|---|---|
| LUMO Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LUMO's share price has been volatile over the past 3 months.
Volatility Over Time: LUMO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 33 | Rick Hawkins | lumos-pharma.com |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease.
Lumos Pharma, Inc. Fundamentals Summary
| LUMO fundamental statistics | |
|---|---|
| Market cap | US$20.43m |
| Earnings (TTM) | -US$34.03m |
| Revenue (TTM) | US$2.05m |
9.7x
P/S Ratio-0.6x
P/E RatioIs LUMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUMO income statement (TTM) | |
|---|---|
| Revenue | US$2.05m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.05m |
| Other Expenses | US$36.09m |
| Earnings | -US$34.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.20 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,659.39% |
| Debt/Equity Ratio | 0% |
How did LUMO perform over the long term?
See historical performance and comparison